As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cer

One of the first en­trants in the PD-(L)1 mar­ket in Chi­na, British drug­mak­er As­traZeneca is now look­ing to ce­ment its ad­van­tage there with an­oth­er ap­proval for check­point in­hibitor Imfinzi.

Imfinzi was ap­proved by Chi­na’s NM­PA as a com­bi­na­tion with plat­inum-based chemother­a­py for first-line use in “ex­ten­sive-stage” small cell lung can­cer, an ad­vanced form of the dis­ease as­so­ci­at­ed with par­tic­u­lar­ly poor out­comes for pa­tients, the drug­mak­er said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.